2[1]Odds FC,Bemaerts R.CHROMagar Candida,a new differential isolation medium for presumptive identification of clinically important candida species[J].J Clin Microbiol,1994,32:1923.
3[2]Alfonso JC.Muticenter evaluation of Neo-Sensititabs,a standardized diffusion method for yeast susceptibility testing[J].Rev lberoam Micol, 1999,16:92.
4[4]Meis J.A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion[J].Dig Micro and Inf Dis,2003,36:215.
5[5]Arikan S,Rex JH.New agents for the treatment of systemic fungal infections-current status[J].Expert Opin Emerging Drugs,2002,7: 3.
6Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study[J]. Clin Infect Dis, 2004,39:309-317.
7Rees JR, Pinner RW, Hajjeh RA, et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance[J]. Clin Infect Dis, 1998,27 : 1138-1147.
8Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections[J]. Clin Microbiol Rev,2002,15:465-484.
9NCCLS. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Proposed Guideline[S]. NCCLS document M44-P[ISBN 1-56238-488-0]. NCCLS, Pennsylvania, USA,2003.
10Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives[J]. Swiss Med Wkly, 2002,132 :303-311.
